Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.

  
    
  
  
    
      Pfizer (NYSE:PFE) announced today that it has completed the cash tender 
      offer to purchase all of the outstanding shares of common stock of Coley 
      Pharmaceutical Group, Inc. (Nasdaq:COLY). The tender offer expired, as 
      scheduled, at midnight, Eastern time, on Friday, December 28, 2007. The 
      offer was not extended.
    
    
      A total of 24,050,054 shares of Coley common stock were validly tendered 
      and not withdrawn prior to the expiration of the offer, including 
      661,444 shares subject to guaranteed delivery procedures. Through its 
      indirect wholly owned subsidiary, Corvette Acquisition Corp., Pfizer has 
      accepted for payment all validly tendered shares. The shares accepted 
      for payment, together with the shares previously owned by Corvette 
      Acquisition Corp., represent approximately 92.2 percent of Coley’s 
      outstanding common shares.
    
    
      As the final step of the acquisition process, Pfizer intends to 
      consummate a merger in which remaining Coley shareholders will receive 
      the same $8.00 cash price per share paid in the tender offer. 
      Consummation of the merger is expected to occur within the next several 
      days. Following the merger, Coley will become an indirect wholly owned 
      subsidiary of Pfizer.